Introduction {#tca12756-sec-0005}
============

Lung cancer is the leading cause of cancer‐related death worldwide. Most patients with lung cancer are diagnosed at an advanced stage, and the current five‐year survival rate is only 18.1%.[1](#tca12756-bib-0001){ref-type="ref"} However, the five‐year survival rate in patients with resected stage I non‐small cell lung cancer (NSCLC) can be as high as 83%.[1](#tca12756-bib-0001){ref-type="ref"} This difference is a result of the principle that detecting tumors at a smaller size and earlier stage, when treatment is more effective, results in a reduction in lung cancer mortality.[2](#tca12756-bib-0002){ref-type="ref"}, [3](#tca12756-bib-0003){ref-type="ref"} Lung adenocarcinoma is now the most common histologic type of NSCLC, accounting for 40% of all NSCLCs.[1](#tca12756-bib-0001){ref-type="ref"} Lung adenocarcinoma is difficult to detect by bronchoscopy or sputum cytology, because it usually arises in peripheral lung tissue and originates from the smaller airways.[4](#tca12756-bib-0004){ref-type="ref"}

Based on recent results from the National Lung Screening Trial, low‐dose computed tomography has been suggested as a screening tool for lung cancer.[5](#tca12756-bib-0005){ref-type="ref"} This trial demonstrated an encouraging 20% relative reduction in lung cancer‐specific mortality compared to screening by chest radiography.[5](#tca12756-bib-0005){ref-type="ref"} However, improved sensitivity is associated with several problems, for example, overdiagnosis and complications from invasive diagnostic procedures on detected nodules. Thus, development of an adequate method for early detection remains an important issue in the management of lung adenocarcinoma.

Exosomes, small membrane vesicles 30--100 nm in size, are actively released from multiple cell types, including dendritic cells, lymphocytes, and tumor cells by exocytosis.[6](#tca12756-bib-0006){ref-type="ref"} They mediate cell‐to‐cell communication by transferring proteins, lipids, and nucleic acids between cells, resulting in the transformation of wild‐type cells into malignant cells.[7](#tca12756-bib-0007){ref-type="ref"}, [8](#tca12756-bib-0008){ref-type="ref"} As a diagnostic cancer marker, exosomes have been evaluated in many malignant tumors, such as melanoma and ovary, prostate, and cervical cancers.[9](#tca12756-bib-0009){ref-type="ref"}, [10](#tca12756-bib-0010){ref-type="ref"}, [11](#tca12756-bib-0011){ref-type="ref"}, [12](#tca12756-bib-0012){ref-type="ref"}, [13](#tca12756-bib-0013){ref-type="ref"}, [14](#tca12756-bib-0014){ref-type="ref"} Only a few small‐scale studies have explored the potential of exosomes as diagnostic biomarkers in lung adenocarcinoma.[15](#tca12756-bib-0015){ref-type="ref"}, [16](#tca12756-bib-0016){ref-type="ref"}, [17](#tca12756-bib-0017){ref-type="ref"} Until now, membrane proteins such as CD91, CD317, and EGFR, as well as a panel of 12 microRNAs (miRNAs), have been shown to be potential exosomal markers of NSCLC.[15](#tca12756-bib-0015){ref-type="ref"}, [16](#tca12756-bib-0016){ref-type="ref"}, [17](#tca12756-bib-0017){ref-type="ref"}

MiRNAs are non‐coding RNA molecules approximately 22--23 nucleotides long that regulate gene expression in organisms ranging from nematodes to humans.[18](#tca12756-bib-0018){ref-type="ref"} In recent years, numerous oncogenic miRNAs associated with lung cancer tumorigenesis have been reported.[19](#tca12756-bib-0019){ref-type="ref"} The majority of miRNAs are intracellular, and only a small number has been detected extracellularly, including in various bodily fluids.[20](#tca12756-bib-0020){ref-type="ref"}, [21](#tca12756-bib-0021){ref-type="ref"}, [22](#tca12756-bib-0022){ref-type="ref"} Extracellular miRNAs are remarkably stable despite high extracellular RNase activity,[22](#tca12756-bib-0022){ref-type="ref"} suggesting that these miRNAs are protected from RNase digestion. Recent studies have confirmed that extracellular miRNAs are packaged in specific extracellular vesicles -- exosomes -- thereby shielding them from RNase degradation.[7](#tca12756-bib-0007){ref-type="ref"}, [21](#tca12756-bib-0021){ref-type="ref"}

Based on their biological functions and stability, exosomal miRNAs may be a promising class of potential noninvasive biomarkers for lung cancer. The objective of this pilot study was to investigate whether exosomal miRNAs detected in bronchoalveolar lavage (BAL) fluid provide a useful biomarker for diagnosis of early‐stage lung adenocarcinoma.

Methods {#tca12756-sec-0006}
=======

Patient samples {#tca12756-sec-0007}
---------------

We prospectively obtained BAL samples from 13 lung adenocarcinoma patients and 15 control patients with non‐tumor pathology (e.g. interstitial lung disease \[ILD\]), between December 2014 and 2015. Bronchoscopy was clinically indicated in these patients to complement the diagnostic process. Lung adenocarcinoma patients at pathological stage I or II according to the International Association for the Study of Lung Cancer 7th Tumor Node Metastasis staging system were included in this study. The most frequent pathologies in patients with ILD were nonspecific interstitial pneumonia (*n* = 4), chronic eosinophilic pneumonia (*n* = 3), sarcoidosis (*n* = 2), cryptogenic organizing pneumonia (*n* = 2), hypersensitivity pneumonitis (*n* = 2), idiopathic pulmonary fibrosis (*n* = 1), and acute eosinophilic pneumonia (*n* = 1). BAL cells were pelleted by centrifugation at 400 × *g* for 10 minutes at 4°C, and the cell‐free supernatant was stored at −80°C prior to exosome isolation.

The study protocol was approved by the medical research committee of the College of Medicine and Health Sciences, and was conducted in accordance with the ethical guidelines of the 1975 Helsinki Declaration. Informed consent was obtained from all participants, as approved by the institutional review board of the Pusan National University Hospital (H‐1411‐005‐023).

Exosome isolation from bronchoalveolar lavage (BAL) fluid {#tca12756-sec-0008}
---------------------------------------------------------

Exosomes were isolated from BAL fluid using a commercial kit according to manufacturer protocols (ExoQuick Exosome Precipitation Solution, System Biosciences, Palo Alto, CA, USA). In brief, BAL fluid was centrifuged at 3000 × *g* for 15 minutes to remove cells and cell debris, and then the appropriate volume of precipitation solution was added to the BAL fluid, followed by centrifugation at 1500 × *g* for 30 minutes. The pellet was stored at −80°C for subsequent applications.

MicroRNA (MiRNA) extraction {#tca12756-sec-0009}
---------------------------

Exosomal miRNAs were isolated using the mirVana miRNA Isolation Kit (Ambion, Austin, TX, USA) after RNase A (Qiagen GmbH, Hilden, Germany) digestion of miRNAs outside of the exosomes. Reverse transcription and quantitative PCR were performed using the MicroRNA TaqMan Reverse Transcription Kit and TaqMan MicroRNA Assay (Applied Biosystems, Foster City, CA, USA) to identify candidate miRNAs (miR‐7, miR‐21, miR‐126, Let‐7a, miR‐17, and miR‐19). Data were analyzed with MxPro--Mx3005P v.3.00 (Stratagene, La Jolla, CA, USA) with the automatic comparative threshold cycle (C~t~) setting for adapting baseline values and determining the C~t~ threshold. Expression levels of mature miRNAs were normalized to that of U6 (2^−ΔCt^), and the fold change in each miRNA was calculated from differences in expression level between lung adenocarcinoma and controls.

Statistical analysis {#tca12756-sec-0010}
--------------------

Given the small sample sizes, miRNA levels were compared using the Mann--Whitney *U* test. SPSS version 18.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analyses. *P* values \< 0.05 were considered statistically significant.

Results {#tca12756-sec-0011}
=======

Characteristics of patients with lung adenocarcinoma {#tca12756-sec-0012}
----------------------------------------------------

The characteristics of the 13 patients enrolled in this study are summarized in Table [1](#tca12756-tbl-0001){ref-type="table"}. The mean age of the patients was 62 years, and seven patients (53.8%) were male. The most common location of the primary tumor was the lower lobe of the right lung (*n* = 6, 46.2%). The mean size of the primary tumor was 2.7 cm (range 1.4--4.6 cm).

###### 

Lung adenocarcinoma patient characteristics

  Cases   Gender    Age   Tumor location  Tumor size (cm)    Pathologic stage
  ------- -------- ----- ---------------- ----------------- ------------------
  1       Male      70         RLL        4.5                       IB
  2       Male      68         RLL        3.4                      IIA
  3       Female    58         RLL        1.7                       IA
  4       Female    57         RLL        2.9                       IA
  5       Female    47         RLL        4.6                      IIA
  6       Male      72         LLL        1.8                       IA
  7       Male      50         LUL        2.0                       IA
  8       Male      69         RUL        1.4                       IA
  9       Female    67         RLL        2.2                      IIA
  10      Female    55         LUL        3.9                       IB
  11      Male      72         RML        2.1                       IA
  12      Male      58         RML        2.5                       IA
  13      Female    67         RML        2.2                       IA

LLL, left lower lobe; LUL, left upper lobe; RLL, right lower lobe; RML, right middle lobe; RUL, right upper lobe.

Differences in exosomal miRNA levels in the BAL fluid of lung adenocarcinoma patients and controls {#tca12756-sec-0013}
--------------------------------------------------------------------------------------------------

Based on previous reports, six miRNAs (miR‐7, 17, 19, 21, 126, and Let‐7a) were chosen for investigation in this study.[23](#tca12756-bib-0023){ref-type="ref"} These six miRNAs have demonstrated diagnostic value for lung adenocarcinoma. The six miRNAs were quantified from exosomes derived from the BAL fluid samples of 13 lung adenocarcinoma patients and 15 controls (patients with benign lung diseases). Exosomal miRNA‐126 (*P* \< 0.001) and Let‐7a (*P* = 0.015) levels were significantly higher in the BAL fluid of lung adenocarcinoma patients than in control subjects (Fig [1](#tca12756-fig-0001){ref-type="fig"}). There were no significant differences in other miRNA levels in BAL fluid between the two groups.

![(**a**) Exosomal miRNA‐126 (*P* \< 0.001) and (**b**) Let‐7a (*P* = 0.015) levels in the bronchoalveolar lavage fluid of lung adenocarcinoma patients (*n* = 13) and control subjects (*n* = 15).](TCA-9-911-g001){#tca12756-fig-0001}

Validation of BAL fluid exosomal miRNAs in tumor tissues {#tca12756-sec-0014}
--------------------------------------------------------

These two miRNAs were validated in independent samples of paired lung adenocarcinoma and normal lung tissues (*n* = 4). MiRNA‐126 was upregulated in the cancer samples relative to the corresponding normal lung tissues (*P* = 0.039); however, there was no difference in Let‐7a level between the groups (Fig [2](#tca12756-fig-0002){ref-type="fig"}).

![(**a**) Exosomal miRNA‐126 (*P* = 0.039) and (**b**) Let‐7a (*P* = 0.258) levels in the samples of paired lung adenocarcinoma and normal lung tissues (*n* = 4).](TCA-9-911-g002){#tca12756-fig-0002}

Discussion {#tca12756-sec-0015}
==========

The value of miRNAs present in tumor‐derived exosomes has been intensively explored as a promising tool for diagnostic and prognostic methods in human cancers.[24](#tca12756-bib-0024){ref-type="ref"} Exosomes play an important role, not only as vehicles of intercellular communication, but also by transferring their contents to nearby cells. During this process, they specifically modulate the surrounding microenvironment, leading to tumor development and progression, thus affecting the therapeutic response.[23](#tca12756-bib-0023){ref-type="ref"}

There has been intensive research into the role of miRNAs in exosomes in NSCLC, as very little is known to date. In 2009, Rabinowits *et al*. reported a significant difference in total exosome and miRNA levels between lung cancer patients and controls and found similarities between the patterns of circulating exosomal miRNAs and those of tumor‐derived miRNAs.[15](#tca12756-bib-0015){ref-type="ref"} These results were the first to suggest that circulating exosomal miRNAs are useful as a screening test for lung adenocarcinoma. Many studies have used exosomal miRNAs isolated from plasma or serum, but few have examined exosomes in BAL fluid since the first study conducted by Admyre *et al*.[25](#tca12756-bib-0025){ref-type="ref"}

Recently, exosomes isolated from BAL fluid in patients with lung neoplasms were investigated, but exosomal miRNAs were not included in that investigation.[26](#tca12756-bib-0026){ref-type="ref"} To our knowledge, no previous studies have investigated the diagnostic value of exosomal miRNAs from BAL fluid in early‐stage lung cancer. In this prospective study, we demonstrated the presence of miRNAs in exosomes from the BAL fluid of both lung cancer patients and those with other lung diseases. We also showed that exosomal miRNAs, especially miR‐126 and Let‐7a, exhibited diagnostic value for early‐stage lung adenocarcinoma. However, upregulation of Let‐7a in BAL fluid was not confirmed in tumor tissues, which may have been a result of the small sample size.

MiR‐126 has been shown to act as both a tumor suppressor and an oncogene, depending on the type of cancer. In general, miR‐126 expression is decreased in lung cancer cell lines, whereas increased expression of miR‐126 inhibits proliferation of NSCLC cells in vitro and prevents tumor growth by targeting EGFL7.[27](#tca12756-bib-0027){ref-type="ref"} In this study, we examined exosomal miRNAs in BAL fluid from early‐stage lung adenocarcinoma patients using a commercial kit. We identified a close correlation between BAL fluid exosomal miRNAs and tumor miRNAs. Thus, BAL fluid exosomal miRNAs obtained by noninvasive methods could serve as diagnostic biomarkers of early‐stage lung adenocarcinoma.

There are some limitations to our study, including the small sample size. Because of the small sample, we could not determine whether there was an association between exosomal miRNA levels and clinical characteristics. Despite these limitations, our study confirmed the presence of miRNAs in exosomes from BAL fluid of both lung cancer patients and those with other lung diseases. Although the clinical feasibility of using exosomal miRNAs for lung cancer diagnosis was not confirmed, our results suggest the role of exosomal miRNAs in BAL fluid as a potential early diagnostic biomarker of lung cancer. These results need to be further investigated by larger, multi‐center prospective studies. In addition, the role of exosomal miRNAs as biomarkers for predicting patient prognosis and response to chemotherapy should be investigated in long‐term follow‐up studies.
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